GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Goldenwell Biotech Inc (OTCPK:GWLL) » Definitions » EBIT

Goldenwell Biotech (Goldenwell Biotech) EBIT : $-0.11 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Goldenwell Biotech EBIT?

Goldenwell Biotech's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-0.03 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.11 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Goldenwell Biotech's annualized ROC % for the quarter that ended in Mar. 2024 was -70.86%. Goldenwell Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -71.26%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Goldenwell Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -0.35%.


Goldenwell Biotech EBIT Historical Data

The historical data trend for Goldenwell Biotech's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Goldenwell Biotech EBIT Chart

Goldenwell Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EBIT
-0.01 -0.12 -0.99 -0.12

Goldenwell Biotech Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.03 -0.04 -0.02 -0.03

Competitive Comparison of Goldenwell Biotech's EBIT

For the Packaged Foods subindustry, Goldenwell Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Goldenwell Biotech's EV-to-EBIT Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Goldenwell Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Goldenwell Biotech's EV-to-EBIT falls into.



Goldenwell Biotech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Goldenwell Biotech  (OTCPK:GWLL) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Goldenwell Biotech's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-0.124 * ( 1 - 0% )/( (0.175 + 0.175)/ 2 )
=-0.124/0.175
=-70.86 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Goldenwell Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.124/( ( (0 + max(0.174, 0)) + (0 + max(0.174, 0)) )/ 2 )
=-0.124/( ( 0.174 + 0.174 )/ 2 )
=-0.124/0.174
=-71.26 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0.175 + 2.7755575615629E-17) - (0 + 0.001 + 0)
=0.174

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0.175 + 2.7755575615629E-17) - (0 + 0.001 + 0)
=0.174

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Goldenwell Biotech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=-0.114/32.402
=-0.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Goldenwell Biotech EBIT Related Terms

Thank you for viewing the detailed overview of Goldenwell Biotech's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Goldenwell Biotech (Goldenwell Biotech) Business Description

Traded in Other Exchanges
N/A
Address
2071 Midway Drive, Twinsburg, OH, USA, 44087
Goldenwell Biotech Inc is engaged in the research and development, production and sales of health care and supplements products. Its products comprise JI MAI - Bovine Cardiac Vascular Active Peptide, Double Proline AG - 3D Active Collagen Peptide, Cartilage Peptide - Type II collagen peptide, and Sugar Master.
Executives
Li Yang director, 10 percent owner, officer: Treasurer C/O GOLDENWELL BIOTECH, INC., 2071 MIDWAY DRIVE, TWINSBURG OH 44087
Hua Xie director, officer: Secretary C/O GOLDENWELL BIOTECH, INC., 2071 MIDWAY DRIVE, TWINSBURG OH 44087
Shuang Liu director, 10 percent owner, officer: Chief Executive Officer C/O GOLDENWELL BIOTECH, INC., 2071 MIDWAY DRIVE, TWINSBURG OH 44087

Goldenwell Biotech (Goldenwell Biotech) Headlines

No Headlines